ANDA approval rate has been on a steady rise post-COVID, from the low of 540 in CY21 to ~700+ annual approvals in CY23E, backed by a reduction in approval timeline and clearance of the backlog.

Aurobindo Pharma has received a Form 483 with one observation from the US FDA after an inspection of its formulation production facility in Andhra Pradesh. The observation is procedural in nature and the company intends to respond to the FDA and work to resolve the issue promptly. A Form 483 is issued when violations of relevant acts are observed during an inspection.

Aurobindo Pharma said that it will respond to the US FDA within the stipulated timelines and work closely with US FDA to close the observation at the earliest.

The US FDA conducted an inspection at Aurobindo Pharma Limited, Bachupally Village, Telangana from July 14-21

Explore the significance of the Relative Strength Index (RSI) in assessing stock movements as we delve into the top 10 stocks that witnessed a decline in their RSI. Discover how this crucial indicator can aid investors in making informed decisions.

As per reports, the promoters of the firm have started the process of selling a majority stake in its injectables business Eugia Pharma

Aurobindo Pharma promoters have begun the process of selling a majority stake in its injectables business, Eugia Pharma Specialities, after negotiations with potential suitors failed to meet valuation expectations. The promoters have hired investment bank Moelis to manage the sale.

KR Choksey recommended accumulate rating on Aurobindo Pharma with a target price of Rs 907 in its research report dated August 24, 2023.

The recalls were reported in the daily US Food and Drug Administration Recall Information updates on 21 August, 2023

Alembic Pharmaceuticals and Aurobindo Pharma are recalling products in the US due to manufacturing problems. Alembic is recalling 82,400 bottles of Tobramycin Ophthalmic Solution due to “Failed Impurities/Degradation Specifications.” Meanwhile, Aurobindo Pharma is recalling 48 bottles of Rufinamide Tablets, in both 200 mg and 400 mg doses, due to cGMP (current good manufacturing practice) deviations, USFDA said. The batch was released prior to approval. Rufinamide tablets are used to treat seizure disorders.

Motilal Oswal recommended Neutral rating on Aurobindo Pharma with a target price of Rs 910 in its research report dated August 14, 2023.

The tablet will used for the treatment of children living with HIV weighing 6 kg to 25 kg and aged at least three months.

Prabhudas Lilladher recommended accumulate rating on Aurobindo Pharma with a target price of Rs 900 in its research report dated August 14, 2023.

The approval granted by the US Food & Drug Administration (USFDA) is for Icatibant injection of strength 30 mg/3 mL (10 mg/mL), single-dose pre-filled syringe, Aurobindo Pharma said in a regulatory filing.

Stocks that were in focus include names like Motilal Oswal which closed with gains of over 3%, Aurobindo Pharma which rose over 1% to a fresh 52-week high and ESAB India which settled 3% higher on Monday.

"If people are focusing on export led sectors, we could have a move out of tech into pharma continuing. I think it has already begun. Strangely, the well-integrated consolidated metals and commodity players could also be in focus. Especially the well-integrated steel sector could be like a new pharma in a mini sense where the worst is taken care of."

With the product pipeline continuing to advance, and execution of growth drivers proceeding as planned, the company is confident that its fundamental strengths position it to create an upward trajectory, Vice-Chairman and Managing Director K Nithyananda Reddy said.

Revenue from operations came in at Rs 6,850.50 crore, up 10 percent from Rs 6,236 crore in the same quarter of the previous fiscal, the company said.

The data was sourced from BSE at 2.50 pm, and the updates from the real-time data could come with a lag. The below data also pertains only to the time at which it was taken.

The BSE MidCap index stocks reached new 52-week highs, reflecting robust market performance and investor optimism. Alkem Laboratories, Aurobindo Pharma, Lupin, and others emerged as the frontrunners, making significant strides in their respective industries.

The company's board of directors will meet on August 12, 2023, to consider and approve the standalone and consolidated unaudited financial results of the company for the first quarter ended June 30, 2023.

#AUROPHARMA AUROPHARMA making WEDGE PATTERNtrade on breakout side

Aurobindo Pharma will also pour in investments worth $100 million in the new subsidiary.

The approval granted by the US Food & Drug Administration (USFDA) is to manufacture and market Plerixafor Injection of strengths 24 mg/1.2 mL (20 mg/mL), single-dose vial, Aurobindo Pharma said in a regulatory filing.

Aurobindo Pharma said Plerixafor injection is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilise hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM).

The S&P BSE MidCap Index saw an impressive display of strength on July 24, 2023, with companies like Aurobindo Pharma, Canara Bank, and General Insurance Corporation leading the rally.

The observations are procedural in nature and we will respond to the USFDA within the stipulated timelines, company said in its release.

After its Q1 results, Ashok Leyland achieved a new 52-week high at Rs. 183.25 on July 21, 2023. As a major player in the automotive industry, Ashok Leyland is renowned for manufacturing commercial vehicles.

The company, spun off from Glenmark Pharmaceuticals in 2019 to focus on the API business, said total revenue from operations climbed 18% to 5.87 billion rupees during the quarter, with regulated markets including the U.S., Europe and India contributing 78%.

“It is tough to define what is the best strategy in consumer stocks. Whether we keep on accumulating slowly or try to time it near over the next couple of months is something we need to see. But the overall story for consumer durables should definitely improve.”

Aurobindo Pharma has undergone a significant reorganisation, restructuring its operations into three subsidiaries. Eugia Pharma Specialities is dedicated to injectables and specialty oral solid dosages; Curateq Biologics focusing on vaccines, biosimilars, and peptides; Apitoria Pharma, an API division.

Aurobindo Pharma, incorporated in the year 1986, is a Large Cap company (having a market cap of Rs 44792.08 Crore) operating in Pharmaceuticals sector.

Aurobindo Pharma, incorporated in the year 1986, is a Large Cap company (having a market cap of Rs 44792.08 Crore) operating in Pharmaceuticals sector.

The VAI status means that the US Food and Drug Administration will not take any regulatory action because the objectionable conditions if found are minor and may not qualify for any action.

Net Sales are expected to increase by 5.1 percent Y-o-Y (up 1.3 percent Q-o-Q) to Rs. 6,555.2 crore, according to Prabhudas Lilladher.

Net Sales are expected to increase by 5.1 percent Y-o-Y (up 1.3 percent Q-o-Q) to Rs. 6,555.2 crore, according to Prabhudas Lilladher.

Aurobindo Pharma Ltd on Wednesday said its wholly-owned subsidiary APL Healthcare has received a final approval from the US health regulator for generic Sevelamer hydrochloride tablets used to control serum phosphorus in patients with chronic kidney disease (CKD) on dialysis. The approval granted by the USFDA to make and market Sevelamer hydrochloride is for tablets of strengths 400 mg and 800 mg, Aurobindo Pharma said.

The pharmaceutical sector, recovering from a challenging period, is now on the upswing said Jyotivardhan Jaipuria. Jaipuria's optimism stems from both the sector's bounce back after a difficult year and the stabilization of pricing pressures in the US generic market.

Under the terms of the agreement, CuraTeQ has been granted exclusive license rights to commercialise BFI-751 in all major regulated markets, certain semi-regulated, and emerging markets worldwide.

Mid-sized companies in India are demonstrating strength and growth potential, as reflected in the surge witnessed by the S&P BSE MidCap index. Stocks of companies such as Abbott India, Colgate-Palmolive, Godrej Properties, and Lodha hit new 52-week highs, showcasing their market appeal and resilience.

Aurobindo Pharma, incorporated in the year 1986, is a Large Cap company (having a market cap of Rs 43801.84 Crore) operating in Pharmaceuticals sector.

This phase 3 study is a multi-centre, randomized, double-blinded study involving females with metastatic HER2- positive breast cancer, company said.

​Chart patterns suggest that the zone of 18,900-18,950 for the Nifty will be strong support going forward. Until the index sustains above the level of 18,900, we may witness the continuation of this strong momentum up to the level of 19,450-19,500. However, if the index slips below 18,900, profit booking up to 18,650-18,500 could be witnessed. Options data suggest a broader trading range of 18,900-19,500 for the upcoming week.

The share touched a 52-week high of Rs 741.40 and a 52-week low of Rs 397.30 on 28 June, 2023 and 03 February, 2023, respectively.

Auditors uncovered “deficient” manufacturing equipment cleaning and storage controls during a visit last month to an Aurobindo Pharma Ltd. facility in Anakapalli, eastern India, according to a FDA report obtained by Bloomberg News through a Freedom of Information Act request.

The Nifty Midcap index saw multiple stocks reach new 52-week highs, demonstrating resilience amidst market uncertainties. Notable performers include Coforge, Trent, Godrej Properties, Lupin, Aurobindo Pharma, Zydus Lifesciences, Power Finance Corporation, and Aditya Birla Capital. These companies showcased strong performance, driven by factors such as navigating the digital landscape, capturing consumer demand, capitalizing on housing needs, innovative healthcare solutions, dedication to research and development, healthcare solutions, strategic investments in the power sector, and diverse financial services.

Commenting on Nifty scaling a new lifetime high, Santosh Meena, Head of Research, Swastika Investmart, said that the 50-stock index surged to an unprecedented all-time high on account of solid fundamentals of the Indian economy and the consistent stability in global cues witnessed recently.

“For Aurobindo Pharma, our official rating is market performance. We do not recommend it from a long-term perspective. It is only a tactical recommendation for the next couple of quarters for the reasons that you just read out. In the case of Gland Pharma, Bernstein sees operational leverage.”

Indian markets had a mixed end on Monday, with Nifty ending at 18,691, up by 0.14%, while Sensex recorded a slight dip of 62,970. However, Nifty Midcap100 registered around 1% increase. Political instability in Russia, which led to an increase in oil prices, had a negative impact on the global market. But on the domestic front, the market experienced limited downside as the pharma and auto sectors provided support. Vinod Nair, Head of Research at Geojit Financial Services, expects investor confidence to be restored in the mid and small-cap segments.

Dr Reddy's Laboratories, HCL Technologies, and Aurobindo Pharma have achieved 52-week highs and solidified their positions as market leaders. Dr Reddy's Laboratories has a market capitalization of Rs 84,254.00 crore and a P/E ratio of 18.7, while HCL Technologies has a market capitalization of Rs 317,037.50 crore and a P/E ratio of 21.3. Aurobindo Pharma has a market capitalization of Rs 42,213.90 crore and a P/E ratio of 21.9, highlighting their growth potential and investor appeal. Their successes serve as a reminder of the growth potential within the BSE 100 index.

Several BSE Midcap stocks achieved their 52-week high, including PB Fintech and ICICI Securities. Aurobindo Pharma showcased impressive performance with its consistent growth. PB Fintech's remarkable achievement and SJVN's success reflect the positive market outlook for midcap stocks.

The European Medicines Agencys (EMA) Committee has accepted Aurobindo Pharma subsidiary CuraTeQ Biologics' request to withdraw the applications for marketing authorization of ZEFYLTI (a filgrastim biosimilar) and DYRUPEG (a pegfilgrastim biosimilar).

Shares of Aurobindo Pharma went up by 3% after the company announced that its subsidiary Eugia Pharma has signed a voluntary license with Medicines Patent Pool to create and market a generic version of Nilotinib Capsules. Aurobindo Pharmas wholly-owned subsidiary Eugia Pharma Specialities has entered a voluntary sublicensing agreement with Medicines Patent Pool to manufacture and market the drug in 44 low and middle-income countries for the treatment of chronic myeloid leukemia.

The sub-licensing agreement for Nilotinib capsules, originally developed by Novartis, will be in 44 low and middle-income countries (LMIC), including the seven countries where patents on the product are pending or in force, Aurobindo Pharma said in a regulatory filing.

India's Aurobindo Pharma has announced that its subsidiary Eugia Pharma Specialities has signed a voluntary sub-licensing agreement with Medicines Patent Pool to develop and market an anti-cancer drug- Nilotinib capsules. Nilotinib capsules are used for the treatment of chronic myeloid leukemia.

Eugia Pharma has signed a voluntary sub-licensing agreement with Medicines Patent Pool to make and sell Nilotinib capsules, originally developed by Novartis, for chronic myeloid leukemia in 44 low and middle-income countries